Spontaneous expectoration of pulmonary metastases in a child with osteogenic sarcoma

Peer Reviewedhttps://deepblue.lib.umich.edu/bitstream/2027.42/148355/1/pbc27611.pdfhttps://deepblue.lib.umich.edu/bitstream/2027.42/148355/2/pbc27611_am.pd

A phase I trial of the trifunctional anti Her2 × anti CD3 antibody ertumaxomab in patients with advanced solid tumors

Background: Ertumaxomab (ertu) is a bispecific, trifunctional antibody targeting Her2/neu, CD3 and the Fcγ-receptors I, IIa, and III forming a tri-cell complex between tumor cell, T cell and accessory cells. Methods: Patients (pts) with Her2/neu (1+/SISH positive, 2+ and 3+) expressing tumors progressing after standard therapy were treated to investigate safety, tolerability and preliminary efficacy. In this study, ertu was applied i.v. in 2 cycles following a predefined dose escalating scheme. Each cycle consisted of five ascending doses (10–500 μg) applied weekly within 28 days with a 21 day treatment-free interval. If 2 pts experienced a dose limiting toxicity (DLT) at a given dose level, the maximum tolerated dose (MTD) had been exceeded. Results: Fourteen heavily pretreated pts (e.g. breast, rectal, gastric cancer) were enrolled in the four main cohorts. Three (21 %) pts had to be replaced. Two serious adverse events (SAE) with possible relation to the investigational drug were seen, both fully reversible. A DLT was not detected. Consequently, the MTD could not be determined. All adverse events (AE) were transient and completely reversible. Most frequent AEs were fatigue (14/14), pain (13/14), cephalgia (12/14), chills (11/14), nausea (8/14), fever (7/14), emesis (7/14) and diarrhea (5/14). Single doses up to 300 μg were well tolerated (total dose up to 800 μg per cycle). We observed one partial remission and two disease stabilizations after first treatment cycle. Conclusions: Single doses up to 300 μg could be safely administered in an escalating dose scheme. Immunological responses and clinical activity warrant further evaluation in patients with Her2 over expressing tumors. Trial registration EudraCT number: 2011-003201-14; ClinicalTrials.gov identifier: NCT0156941

Psychology and aggression

Peer Reviewedhttp://deepblue.lib.umich.edu/bitstream/2027.42/68264/2/10.1177_002200275900300301.pd

Rupture process of large earthquakes in the northern Mexico subduction zone

The Cocos plate subducts beneath North America at the Mexico trench. The northernmost segment of this trench, between the Orozco and Rivera fracture zones, has ruptured in a sequence of five large earthquakes from 1973 to 1985; the Jan. 30, 1973 Colima event ( M s 7.5) at the northern end of the segment near Rivera fracture zone; the Mar. 14, 1979 Petatlan event ( M s 7.6) at the southern end of the segment on the Orozco fracture zone; the Oct. 25, 1981 Playa Azul event ( M s 7.3) in the middle of the Michoacan “gap”; the Sept. 19, 1985 Michoacan mainshock ( M s 8.1); and the Sept. 21, 1985 Michoacan aftershock ( M s 7.6) that reruptured part of the Petatlan zone. Body wave inversion for the rupture process of these earthquakes finds the best: earthquake depth; focal mechanism; overall source time function; and seismic moment, for each earthquake. In addition, we have determined spatial concentrations of seismic moment release for the Colima earthquake, and the Michoacan mainshock and aftershock. These spatial concentrations of slip are interpreted as asperities; and the resultant asperity distribution for Mexico is compared to other subduction zones. The body wave inversion technique also determines the Moment Tensor Rate Functions ; but there is no evidence for statistically significant changes in the moment tensor during rupture for any of the five earthquakes. An appendix describes the Moment Tensor Rate Functions methodology in detail.Peer Reviewedhttp://deepblue.lib.umich.edu/bitstream/2027.42/43169/1/24_2004_Article_BF00875970.pd